A team led by researchers at the Barcelona Biomedical Investigation Institute in Spain has used quantitative real-time PCR and droplet digital PCR to detect and quantify diminished levels of cell-free mitochondrial DNA in cerebrospinal fluid of patients with, or at risk of developing, Alzheimer's disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.